oleum neutralicum

Phase 3Small molecule

SSemmelweis University

oleum neutralicum is one of 19 small molecule programs targeting Hematologic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic DiseaseActive, not recruiting

Hematologic DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Hematologic Disease

#DrugCompanyPhaseTrials

Maxipime

Pfizer

Phase 3

1 2

Cipro

Bayer

Phase 3

1 3

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 4

Neoral

Novartis

Phase 2

4 5

Cellcept

Roche

Phase 2

4 6

Fludara

Sanofi

Phase 2

3 7

Fludara

Sanofi

Phase 2

3 8

Tepadina

Alnylam Pharmaceuticals

Phase 2

2 9

Simulect

Novartis

Phase 2

1 10

Atgam

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematologic Disease1 trial

The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases

Terminated·SSemmelweis University·Phase 3·NCT01518959·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for oleum neutralicum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — oleum neutralicum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for oleum neutralicum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Semmelweis University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSemmelweis University

oleum neutralicum

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematologic Disease1 trial

References

Drug Info

Quick Facts

Related News